Cargando…
TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth
TNK1 is a non-receptor tyrosine kinase with poorly understood biological function and regulation. Here, we identify TNK1 dependencies in primary human cancers. We also discover a MARK-mediated phosphorylation on TNK1 at S502 that promotes an interaction between TNK1 and 14-3-3, which sequesters TNK1...
Autores principales: | Chan, Tsz-Yin, Egbert, Christina M., Maxson, Julia E., Siddiqui, Adam, Larsen, Logan J., Kohler, Kristina, Balasooriya, Eranga Roshan, Pennington, Katie L., Tsang, Tsz-Ming, Frey, Madison, Soderblom, Erik J., Geng, Huimin, Müschen, Markus, Forostyan, Tetyana V., Free, Savannah, Mercenne, Gaelle, Banks, Courtney J., Valdoz, Jonard, Whatcott, Clifford J., Foulks, Jason M., Bearss, David J., O’Hare, Thomas, Huang, David C. S., Christensen, Kenneth A., Moody, James, Warner, Steven L., Tyner, Jeffrey W., Andersen, Joshua L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429728/ https://www.ncbi.nlm.nih.gov/pubmed/34504101 http://dx.doi.org/10.1038/s41467-021-25622-3 |
Ejemplares similares
-
Fusion crystallization reveals the behavior of both the 1TEL crystallization chaperone and the TNK1 UBA domain
por: Nawarathnage, Supeshala, et al.
Publicado: (2023) -
Recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA) versus alteplase (rt-PA) as fibrinolytic therapy for acute ST-segment elevation myocardial infarction (China TNK STEMI): protocol for a randomised, controlled, non-inferiority trial
por: Wang, Hai-bo, et al.
Publicado: (2017) -
Blockade of ACK1/TNK2 To Squelch the Survival of Prostate Cancer Stem-like Cells
por: Mahajan, Nupam P., et al.
Publicado: (2018) -
The noncatalytic regions of the tyrosine kinase Tnk1 are important for activity and substrate specificity
por: Ahmed, Sultan, et al.
Publicado: (2022) -
Epithelial cell extrusion requires the sphingosine-1-phosphate receptor 2 pathway
por: Gu, Yapeng, et al.
Publicado: (2011)